Haruta Masayuki

ハルタマサユキ | Haruta Masayuki

Affiliation and department：
Job title： researcher

Research field (3)： Medical biochemistry , Genomics , Fetal medicine/Pediatrics

Research keywords (9)：ゲノム解析 , DNAメチル化 , 神経芽細胞腫 , 肝芽腫 , ウィルムス腫瘍 , DNA Methylation , neuroblastoma , hepatoblastoma , wilms tumor

Research theme for competitive and other funds (12)：

2023 - 2028 小児腎悪性腫瘍の治療層別化に有効なバイオマーカーを同定するための多施設共同研究
2022 - 2025 The study of pathogenic mechanism and clinical application, in complex chromosomal abnormality and chromothripsis-related leukemia.
2020 - 2023 小児腎腫瘍(腎芽腫)における11p13-14の新規原因遺伝子同定と機能解析
2019 - 2022 思春期若年成人白血病のクロモスリプシスによる悪性化機構解明とゲノム医療への応用
2017 - 2020 バイオマーカーを指標とした小児腎腫瘍に対する新規治療開発

Show all

Papers (60)：

HIROTAKA FUCHIZAWA, KIYOHIRO ANDO, NORIKO MOTOI, TOSHIHIKO IIZUKA, MASAHARU INOUE, KOUKI MITANI, YUTA SANO, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, et al. STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer. Anticancer Research. 2024. 44. 5. 1925-1930
Kiyohiro Ando, Ryo Kurashina, Noriko Motoi, Toshihiko Iizuka, Masaharu Inoue, Riko Maruyama, Kouki Mitani, Hisanori Takenobu, Masayuki Haruta, Ritsuko Onuki, et al. Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma. Biochemical and Biophysical Research Communications. 2023. 676. 165-170
Sultana Parvin, Jesmin Akter, Hisanori Takenobu, Yutaka Katai, Shunpei Satoh, Ryu Okada, Masayuki Haruta, Kyosuke Mukae, Tomoko Wada, Miki Ohira, et al. ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors. BMC Cancer. 2023. 23. 1
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, RITSUKO ONUKI, YOH MATSUOKA, TAKEHIKO KAMIJO, et al. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma. Cancer Diagnosis & Prognosis. 2023. 3. 2. 230-235
Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafune, et al. Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells. Cancer science. 2023

ｍore...

MISC (67)：

迎恭輔, 竹信尚典, 神田浩明, 大平美紀, 遠藤悠紀, 春田雅之, 杉野隆一, 佐藤俊平, 戸口田淳也, 長船健二, et al. iPS細胞由来神経堤細胞による軟骨芽細胞型骨肉腫モデル開発. 日本癌学会総会記事. 2021. 80回. [P11-3]
Mamoru Takada, Yasuhiko Kaneko, Masayuki Haruta, Shigenori Nagai, Kenichi Inoue, Katsunori Toduka, Masafumi Kurozumi, Hiroyuki Takei, Seishi Ogawa, Takeshi Nagashima, et al. BRCA1 alterations with additional defects in DNA damage repair genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy. CANCER RESEARCH. 2020. 80. 4
竹信尚典, 大平美紀, 杉野隆一, サルマンディルバー, サルマンディルバー, 力石浩志, 力石浩志, 岡田龍, 岡田龍, 迎恭輔, et al. Tumor sphere specific gene CDX1 binds to OCT4 and MAX promoters to regulates stemness. 日本癌学会学術総会抄録集(Web). 2020. 79th
迎恭輔, 竹信尚典, 杉野隆一, 大平美紀, 佐藤俊平, 遠藤悠紀, 岡田龍, 春田雅之, 戸口田淳也, 長船健二, et al. iPS細胞由来神経堤細胞の神経芽腫発生メカニズム解析のための細胞モデル開発(Development of neuroblastoma model from iPS-based neural crest cells for analysis of neuroblastoma tumorigenesis). 日本癌学会総会記事. 2018. 77回. 1278-1278
遠藤悠紀, 竹信尚典, 杉野隆一, 春田雅之, 迎恭輔, 佐藤俊平, 秦佳孝, 長谷川真理子, 岡田龍, 片井友貴, et al. 神経芽腫におけるEZH2阻害剤の感受性を制御する分子の探索(Identification of molecules that regulate the sensitivity of EZH2 inhibitor in neuroblastoma). 日本癌学会総会記事. 2018. 77回. 1965-1965

ｍore...

Professional career (1)：

Master(Life Science) (Tottori University)

Work history (2)：

2004/07 - 現在埼玉県立がんセンター臨床腫瘍研究所研究員
2004 - - Saitama Cancer Center, Researcher

Association Membership(s) (4)：

THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY , 日本癌学会 , 日本分子生物学会 , The Molecular Blology Society of Japan

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page